|
Cohort1: CLL_dose level 1
|
| Administration route |
intravenous infusion |
| Dosage |
1E6 cells/kg |
| Donor type |
Autologous |
| Pts |
6 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
Number of Participants Experiencing Dose Limiting Toxicities:0 |
| Adverse reactions |
2/7(All-couse mortality); 4/6(Cardiac disorders; General disorders; Nervous system disorders; Psychiatric disorders; Vascular disorders) |
|
|
Cohort2: CLL_dose level 2
|
| Administration route |
intravenous infusion |
| Dosage |
2E6 cells/kg |
| Donor type |
Autologous |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
Number of Participants Experiencing Dose Limiting Toxicities:0 |
| Adverse reactions |
3/3(All-couse mortality); 2/3(Gastrointestinal disorders; General disorders; Infections and infestations; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified; Vascular disorders) |
|
|
Cohort3: CLL/SLL_dose level 1
|
| Administration route |
intravenous infusion |
| Dosage |
1E6 cells/kg |
| Donor type |
Autologous |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
Number of Participants Experiencing Dose Limiting Toxicities:1 |
| Adverse reactions |
0/3(All-couse mortality); 3/3(General disorders; Infections and infestations; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
|
|
Cohort4: CLL_dose level 1_ibrutinib
|
| Administration route |
intravenous infusion |
| Dosage |
1E6 cells/kg |
| Donor type |
Autologous |
| Pts |
3 |
| Age |
Adult, Older_Adult |
| Lymph depletion |
Yes |
| Outcome |
Number of Participants Experiencing Dose Limiting Toxicities:0 |
| Adverse reactions |
1/3(All-couse mortality); 1/3(Infections and infestations) |
|